![Citalopram and Escitalopram: MOA, Indications, Pharmacokinetics and Dosing - Psychopharmacology Institute Citalopram and Escitalopram: MOA, Indications, Pharmacokinetics and Dosing - Psychopharmacology Institute](https://cdn.psychopharmacologyinstitute.com/wpengine/uploads/20-prescribing-information-citalopram-escitalopram-300x168.png)
Citalopram and Escitalopram: MOA, Indications, Pharmacokinetics and Dosing - Psychopharmacology Institute
![Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10 mg - ScienceDirect Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10 mg - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0924933810001653-gr2.jpg)
Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10 mg - ScienceDirect
![Various doses of MPH with fixed, sub-threshold dose of escitalopram (20... | Download Scientific Diagram Various doses of MPH with fixed, sub-threshold dose of escitalopram (20... | Download Scientific Diagram](https://www.researchgate.net/publication/283540758/figure/fig3/AS:293222636113923@1446921132255/Various-doses-of-MPH-with-fixed-sub-threshold-dose-of-escitalopram-20-mg-kg-were.png)
Various doses of MPH with fixed, sub-threshold dose of escitalopram (20... | Download Scientific Diagram
![Frontiers | CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population Frontiers | CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population](https://www.frontiersin.org/files/Articles/730461/fphar-12-730461-HTML/image_m/fphar-12-730461-g001.jpg)
Frontiers | CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population
![PDF) Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): An open-label, pilot study PDF) Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): An open-label, pilot study](https://www.researchgate.net/profile/Alan-Wade/publication/50408546/figure/tbl1/AS:669622810460183@1536661927895/Dose-schedule_Q320.jpg)
PDF) Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): An open-label, pilot study
![Frontiers | Optimal Dose of Serotonin Reuptake Inhibitors for Obsessive-Compulsive Disorder in Adults: A Systematic Review and Dose–Response Meta-Analysis Frontiers | Optimal Dose of Serotonin Reuptake Inhibitors for Obsessive-Compulsive Disorder in Adults: A Systematic Review and Dose–Response Meta-Analysis](https://www.frontiersin.org/files/Articles/717999/fpsyt-12-717999-HTML/image_m/fpsyt-12-717999-t002.jpg)